Canaccord raised the firm’s price target on Exagen (XGN) to $11 from $8 and keeps a Buy rating on the shares. The firm said the target increase is driven by increased near- and long-term revenue estimates, while noting the company announced 2Q25 results that were ahead of our estimates and FactSet consensus.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen’s Strong Q2 Performance and Growth Strategy Justify Buy Rating
- KeyBanc upgrades Exagen on improved revenue visibility
- Exagen Inc. Reports Record Q2 2025 Revenue
- Exagen’s Promising Financial Trajectory and Raised Price Target Amid Strong Performance and Strategic Growth Initiatives
- Exagen upgraded to Overweight from Sector Weight at KeyBanc